Key clinical trials of molnupiravir (Merck and/or Ridgeback biotherapeutics)

Drug	Indication	Phase	Status	Location(s)	Identifier
Molnupiravir	COVID-19 prevention	III	Recruiting	Multinational	MOVe-AHEAD; NCT04939428; 4482-013; EudraCT2021-000904-39; MK4482-013
Molnupiravir	Non-hospitalized adults with COVID-19	II/III	Stopped early for efficacy	Multinational	MOVe-OUT; NCT04575597; EudraCT2020-003368-24; MK-4482-002; PHRR201209-003186; jRCT2031210148
Molnupiravir	Hospitalized adults with COVID-19	II/III	Discontinued after phase II	Multinational	MOVe-IN; NCT04575584; EudraCT2020-003367-26; MK4482-001
Molnupiravir	Hospitalized adults with COVID-19	II	Recruiting	USA	END-COVID; NCT04405739; EIDD-2801-2004
Molnupiravir	COVID-19	II	Completed	USA	NCT04405570; EIDD-2801-2003